Navigation Links
New test for joint infection could spare some patients an unnecessary procedure
Date:3/3/2008

A potential diagnostic test that could help surgeons confirm or rule out the presence of infection-causing bacteria in prosthetic joints that require surgical revision has been developed by researchers at the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), a part of the National Institutes of Health (NIH). Such a test could spare a subgroup of people who need the surgery a time-consuming and costly treatment for infection, while helping to ensure that people who need the procedure get it. The test is described in the March issue of the Journal of Bone and Joint Surgery.

Each year, hundreds of thousands of joint replacement surgeries are performed in this country. And each year, thousands of them must be revised (the prosthetic joint must be removed and replaced) due to severe pain and swelling. These symptoms are often due to infection, says Rocky S. Tuan, Ph.D., chief of NIAMS' Cartilage Biology and Orthopaedics Branch.

The standard treatment for suspected infection is to remove the joint prosthesis and replace it with a spacer that has been impregnated with antibiotics. After about six weeks, patients must undergo another surgery to remove the spacer. Only then can the surgeon implant the new prosthesis.

The problem with this approach is that confirming the presence of infection-causing bacteria is an inexact science. Currently, doctors check for infection by culturing a sample of the joint fluid. A positive culture confirms live bacteria, making spacer surgery a certainty. A negative culture, however, does not necessarily mean there is no infection. In fact, Tuan says that estimates of the false negative rate for joint cultures in revision surgeries range from 27 percent to 50 percent. But because failure to treat an infected joint could lead to severe infection and limb amputation, spacer surgery is sometimes performed for safety's sake even when infection test results are inconclusive.

To
'/>"/>

Contact: Trish Reynolds
reynoldsp2@mail.nih.gov
301-496-8190
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases
Source:Eurekalert

Page: 1 2 3

Related medicine news :

1. MaxLife Fund Corp. and Capital Growth Planning Inc., sign a joint venture agreement
2. International Federation of Sports Medicine Selects Celadrin(R) Topical Cream as its First and Only Official Joint and Muscle Topical Cream
3. Reynolds American Subsidiary to Receive Payment Following Gallaher Joint-Venture Termination
4. BioMed Realty Trust Joint Venture Enters Into New $245 Million Construction Loan and Extends Term of Existing Loan Facility
5. Joint Commission Alert Shines Light on Preventing MRI Accidents, Injuries
6. Joint Commission, National Quality Forum Now Accepting Applicants for the 2008 John M. Eisenberg Patient Safety and Quality Awards
7. Laser Energetics Provides Joint Venture Update to Shareholders
8. LiquidAgents Healthcare, LLC Awarded Accreditation from the Joint Commission
9. NutraCea Forms Joint Ventures With HerbalScience to Develop Nutraceutical Extracts and Pharmaceutical Chemistries From Stabilized Rice Bran
10. Joint Commission International Achieves Accreditation from ISQua
11. Grubb & Ellis Healthcare REIT Acquires Chesterfield Rehabilitation Center in Chesterfield, Missouri in a Joint Venture with Duke Realty

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)...ether procedure done immediately or 3 weeks later,...ay News) -- Timing of surgical repair or reconstru...ffect patient outcome, a new study has found. ,...atic knee dislocations that can occur in high-impa...ime to perform surgery to repair these injuries ha...
(Date:12/4/2009)...N, Dec. 4 Substantial progress has...e community,s ability to diagnose and treat epilep...ilepsy management has not reached most of the 50 m...the nearly three million people in the United Stat...n C. Schachter, M.D., president of the American Ep...
(Date:12/4/2009)... virus will come back during winter isn,t known, C...News) -- The number of states reporting widespread... -- to 25 from a high of 48 just two weeks ago, a ...the supply of H1N1 swine flu vaccine continues to ....S. Centers for Disease Control and Prevention, sa...
(Date:12/4/2009)...edge of risks, many hesitate to take breast cancer...ealthDay News) -- Worries about side effects are a... at high risk for breast cancer are willing to tak... study finds. , In an effort to inform women ab...rs at the University of Michigan Comprehensive Can...
(Date:12/4/2009)...DISON, Wis., Dec. 4 When... Wisconsin Department of Health Services needed to...than ever before. Join Sonic Foundry, Inc. (Nasd... media webcasting and knowledge management, for a ...n Department of Health Services, will share how in...
Breaking Medicine News(10 mins):Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 2Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 3Health News:Epilepsy Patients Caught in Treatment Gap and Not Getting State-of-the-Art Care 4Health News:Swine Flu Continues to Wane 2Health News:High-Risk Women May Often Avoid Using Tamoxifen 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 2Health News:Live Webinar: Pandemic + Recession = Webcasting: Cost-Effective Streaming for Public Health Communications 3
... Scientists with the Lineberger Comprehensive Canc...hapel Hill have for the first time implicated a g... the inevitable recurrence of advanced prostate ca...es prostate cancer recur in men treated to get rid...
... Researchers at the University of Wisconsin-Madiso... of measuring molecular structures quickly and ac...ld and see the shapes of intermediate steps. ...n that is implicated in type II diabetes. ...
... When compared with intensive drug therapy, percut...s more beneficial in reducing the long-term risk ...rs with 'silent ischemia', according to a study. ...oms of angina (chest pain due to inadequate supply...
... A new study has found that no other lifestyle fac.... A study in the May issue of the Journal ...t have the most impact on periodontal health. ...ferent lifestyle factors on the progression of per...
... A research on animals, conducted by the National ...ence that a chemical referred to as hexavalent chr...med in drinking water. Hexavalent chromiu...The two-year study showed that the mice had develo...
... A review has suggested that women who take a low-...ting, have a reduced risk of pregnancy complicati...31 studies involving more than 32,000 women, found... that women need to be cautious, especially as asp...
Other Medicine News:Health News:Study Implicates Protein as a Trigger of Advanced Prostate Cancer Recurrence 2Health News:New Analytical Tool to Unravel the Cause of Diabetes 2Health News:Angioplasty Reduces Long-term Cardiac Risk in Heart Patients With 'silent' Ischemia 2Health News:Impact of Periodontal Health High With Smoking and Sleeping 2
(Date:12/4/2009)..., Dec. 4 Dynatronics Cor...a sole-source vendor agreement to provide therapy ... Therapy with 65 clinics located in Tennessee and ...le-source supplier to Benchmark Physical Therapy,"...of sales and marketing at Dynatronics. "Benchmark ...
(Date:12/4/2009)...ASHINGTON, Dec. 4 Chem...ublished by the Pharmaceutical Research and Manuf...new drugs and vaccines in development for HIV/AIDS...nd that the 97 products in development include 23 ... in human clinical trials or awaiting approval by ...
(Date:12/4/2009)... Dec. 4 PharmAthene, Inc...ing medical countermeasures against biological and...y is presenting results of a study demonstrating t...n anthrax model in the New Zealand White (NZW) rab...session at the HHS Public Health Emergency Medical...
Breaking Medicine Technology:U.S. Pharmaceutical Companies Developing 97 New Drugs and Vaccines to Fight HIV/AIDS 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 2PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 3PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 4PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 5PharmAthene Presents Animal Model Data for Valortim(R) at the 2009 BARDA Industry Conference / PHEMCE Stakeholders Workshop 6NBTY to Web Cast Fiscal Fourth Quarter Conference Call 60597 1NBTY to Web Cast Fiscal Fourth Quarter Conference Call 60597 2Ethics and Healthcare Reform Panel Community Forum Open to Public November 17 60593 1Ethics and Healthcare Reform Panel Community Forum Open to Public November 17 60593 2Ethics and Healthcare Reform Panel Community Forum Open to Public November 17 60593 3Free 2D 3D Advanced Visualization Software for CT and MRI Now Available From FiatLux Imaging 5946 1Free 2D 3D Advanced Visualization Software for CT and MRI Now Available From FiatLux Imaging 5946 2
...detail how some fair coloring traits contribute to... into the deCODEme(TM) service, REYKJAVIK, Icelan...cientists and academic colleagues from Europe and ... in the genetics of pigmentation,traits in people ...of these,common variants also confer risk of two t...
...lmo BioTech Inc. (OTC,Bulletin Board: PLMO.OB) has...of its Phase I Human Trials with its PulmoBind Mol...monary Embolism and Pulmonary,Hypertension., The ...idiary,PulmoScience Inc., and the title of the wor...olecular Imaging of the Pulmonary Circulation.", ...
Other Medicine Technology:deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 2deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 3deCODE Discovers Novel Genetic Links Between Pigmentation Traits and Risk of Skin Cancer 4Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 2Pulmo BioTech Announces Details of the Methodology for its Phase I Human Trials 3
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
...ference laboratory and a worldwide leader in innov...fers an extensive test menu of highly complex and ...ology. Owned by the University of Utah, ARUP Labor...ion's university teaching hospitals and children's...
Medicine Products: